Omeros: A Bullish Biotech Gem To Buy And Hold

Omeros: A Bullish Biotech Gem To Buy And Hold


We just saw a bear raid attack following a 55% run-up in June following some positive FDA news. Omeros' lead pipeline candidate is OMS721, which is an antibody targeting mannan-binding lectin- associated serine protease-2 , the effector enzyme of the lectin pathway of the complement system.



from Biotech News